Sažetak
Background: To explore the correlation between serum uric acid (SUA) and prognosis in patients with chronic heart failure (CHF) after revascularization.
Methods: A total of 126 patients with CHF undergoing revascularization [coronary artery intervention (PCI) or coronary artery bypass grafting (CABG)] in the hospital were enrolled as CHF group between December 2021 and October 2022, while 126 healthy controls during the same period were enrolled as healthy control group. The levels of SUA, inflammatory factors and cardiac function in the two groups were detected. The correlation between SUA level and inflammatory factors, cardiac function levels was analyzed. All patients in CHF group were followed up for 6 months to observe prognosis. The differences in the above indexes among patients with different prognosis were compared. The risk factors of prognosis were analyzed by multivariate Logistic regression analysis, and their predictive value for prognosis was evaluated by ROC curves analysis.
Results: SUA, IL-6, TNF-α, NT-proBNP and LVEDD in CHF group were higher than those in healthy control group, while LVEF was lower than that in healthy control group (P<0.05). Among the 126 patients within 6 months after surgery, there were 24 cases (19.05%) with adverse cardiac events (poor prognosis). SUA, IL-6, TNF-α, NT-proBNP and LVEDD in patients with poor prognosis were higher than those with good prognosis, while LVEF was lower than that with good prognosis (P<0.05). SUA level was positively correlated with IL-6, TNF-α, NT-proBNP and LVEDD (r=0.283, 0.292, 0.322, 0.355, P<0.05), while negatively correlated with LVEF (r=-0.368, P<0.05). High level of SUA and low LVEF were independent risk factors of prognosis (OR=1.486, 0.678, P<0.05). Both SUA and LVEF were of prognostic value (AUC=0.805, 0.809, P<0.05).
Conclusion: SUA level is significantly increased in CHF patients, which is an independent risk factor of poor prognosis in CHF patients after revascularization, with high prognostic value.
Ključne reči
Array
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.